156 related articles for article (PubMed ID: 2890149)
1. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of famotidine in man.
Kroemer H; Klotz U
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
[TBL] [Abstract][Full Text] [Related]
3. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi K
Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
Morgan MY; Stambuk D; Cottrell J; Mann SG
Aliment Pharmacol Ther; 1990 Feb; 4(1):83-96. PubMed ID: 2104076
[TBL] [Abstract][Full Text] [Related]
7. Effects of prolonged oral cimetidine, ranitidine, and famotidine therapy on antipyrine elimination.
Sakaue H; Akamatsu K; Hirabayashi Y; Sasaki T; Nakanishi K; Okada S; Kanaoka M; Nishinobu M; Masumoto S; Ohta Y
Clin Ther; 1987; 9(6):602-6. PubMed ID: 2894244
[TBL] [Abstract][Full Text] [Related]
8. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
[TBL] [Abstract][Full Text] [Related]
12. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of famotidine in infants.
Wenning LA; Murphy MG; James LP; Blumer JL; Marshall JD; Baier J; Scheimann AO; Panebianco DL; Zhong L; Eisenhandler R; Yeh KC; Kearns GL
Clin Pharmacokinet; 2005; 44(4):395-406. PubMed ID: 15828852
[TBL] [Abstract][Full Text] [Related]
14. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
Okolicsanyi L; Venuti M; Orlando R; Lirussi F; Nassuato G; Benvenuti C
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
Adachi K; Komazawa Y; Mihara T; Azumi T; Fujisawa T; Katsube T; Furuta K; Kinoshita Y
J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
[TBL] [Abstract][Full Text] [Related]
17. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
[TBL] [Abstract][Full Text] [Related]
18. Oxmetidine (SK&F 92994): pharmacokinetic study in patients with in patients with liver cirrhosis.
Miglio F; Baraldini M; Serra S; Facchini A; Stefanini GF; Meliconi R; Gasbarrini G; Labo' G
Int J Clin Pharmacol Res; 1985; 5(6):399-404. PubMed ID: 2869000
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ebrotidine in rats and dogs.
Albet C; Pérez JA; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
[TBL] [Abstract][Full Text] [Related]
20. Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
Savarino V; Mela GS; Scalabrini P; Sumberaz A; Fera G; Zentilin P; Celle G
Am J Gastroenterol; 1988 Sep; 83(9):917-22. PubMed ID: 2901220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]